Robert LaCaze is Chief Executive Officer at Mnemo Therapeutics. He brings 35 years of experience in the biopharmaceutical industry with a specialty in Oncology. Previously as the Executive Vice President and Head of the Oncology Strategic Business Unit at Bayer, Robert oversaw the Oncology franchise of Bayer AG globally. He also served on the Executive Committee for Bayer Pharmaceuticals and served on the Board of Vividion. Before joining Bayer in 2015, Robert was the Senior Vice President and Head of Global Oncology at Bristol-Myers Squibb. He co-led the Oncology Disease Strategy team with direct responsibility to set and implement the vision and strategy for the Oncology franchise, including Immuno-Oncology (I-O). Robert has experiences with Cell Therapies, TKIs, Radiopharmaceuticals, Precision Oncology products with Diagnostics and IO compounds across a range of tumor including both Hem and Solid. He has also directly or oversaw numerous multi-billion dollar Oncology launches. Robert serves on the Louisiana Tech College of Business Administration Advisory Board and is a member of AACR and BioCentury. He serves on the Board for Axiom REACH, a non-profit organization serving the needs of under-privileged cancer patients. He was also named one of New Jersey’s Top 25 Health Care Executives for 2022. Robert received a Bachelor of Science in Marketing from Louisiana Tech University.